• Bicycle Therapeutics PLC BCYC.OQ BCYC.O is expected to show a rise in quarterly revenue when it reports results on February 18 (estimated) for the period ending December 31 2024

• The Cambridge Cambridgeshire-based company is expected to report a 1.9% increase in revenue to $5.432 million from $5.33 million a year ago, according to the mean estimate from 13 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for Bicycle Therapeutics PLC is for a loss of 86 cents per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Bicycle Therapeutics PLC is $30.00​, above​ its last closing price of $12.49. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated February 14 at 13:42 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)